Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])

The summary for the Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44]) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
	CFDA Number:	93.242
	CFDA Description:	Mental Health Research Grants
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-06-027
	Document Type:	Modification to Previous Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Oct 21, 2005
	Creation Date:	Oct 02, 2007
	Original Closing Date for Applications:	Multiple dates, see announcement.
	Current Closing Date for Applications:	Information not provided
	Archive Date:	Jun 07, 2008
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Only United States small business concerns (SBCs) are eligible to submit SBIR applications. A small business concern is one that, at the time of award for both Phase I and Phase II awards, meets all of the following criteria: - Is independently owned and operated, is not dominant in the field of operation in which it is proposing, has a place of business in the United States and operates primarily within the United States or makes a significant contribution to the US economy, and is organized for profit. - Is at least 51% owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States. - Has, including its affiliates, an average number of employees for the preceding 12 months not exceeding 500, and meets the other regulatory requirements found in 13 C.F.R. Part 121. Business concerns are generally considered to be affiliates of one another when either directly or indirectly, (a) one concern controls or has the power to control the other; or (b) a third-party/parties controls or has the power to control both. Control can be exercised through common ownership, common management, and contractual relationships. The term "affiliates" is defined in greater detail in 13 C.F.R. 121.103. The term "number of employees" is defined in 13 C.F.R. 121.106. A business concern may be in the form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust, or cooperative. Further information may be obtained at http://sba.gov/size, or by contacting the Small Business Administration's (SBA) Government Contracting Area Office or Office of Size Standards.
Grant Description: This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications that propose to develop novel pharmacologic agents for brain research related to mental disorders, including research aimed at discovering new drugs for these disorders. In addition, this FOA solicits SBIR grant applications that propose to take existing, promising compounds through the next step of drug discovery and development. Finally, this FOA also encourages SBIR grant applications designed to study the effectiveness of novel interventions.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PA-06-027.html http://grants.nih.gov/grants/guide/pa-files/PA-06-027.html
Grant Announcement Contact: Webmaster, NIH, Webmaster, Phone not available, Fax not available, Email FBOWebmaster@mail.nih.gov FBOWebmaster@mail.nih.gov Webmaster, NIH
Similar Government Grants: • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R21); • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R03); • Advancing the Impact of Effective HIV/AIDS Prevention and Treatment Interventions (R03); • Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R34); • Advancing the Impact of Effective HIV/AIDS Prevention and Treatment Interventions (R34); • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R42]); • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44]); • Pharmacologic Agents and Drugs for Mental Disorders (STTR [R41/R42]); • Solicitation of Assays for High Throughput Screening (HTS) in the Molecular Libraries Screening Cent...; • Competing Renewal Awards of SBIR Phase II Grants for Pharmacologic Agents and Drugs for Mental Disor...